Integra LifeSciences (IART) Expected to Announce Earnings on Thursday

Integra LifeSciences (NASDAQ:IART - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Thursday, July 31st. Analysts expect Integra LifeSciences to post earnings of $0.43 per share and revenue of $395.06 million for the quarter. Integra LifeSciences has set its Q2 2025 guidance at 0.400-0.450 EPS and its FY 2025 guidance at 2.190-2.290 EPS.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 1.78% and a positive return on equity of 12.12%. The business had revenue of $382.65 million for the quarter, compared to analysts' expectations of $381.17 million. During the same period in the previous year, the company earned $0.55 EPS. Integra LifeSciences's revenue for the quarter was up 3.7% compared to the same quarter last year. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Stock Performance

Shares of IART stock traded up $0.40 during trading hours on Friday, reaching $13.11. 956,448 shares of the company traded hands, compared to its average volume of 953,432. The firm has a 50-day moving average price of $12.61 and a 200 day moving average price of $17.96. The company has a market cap of $1.02 billion, a P/E ratio of -34.50, a P/E/G ratio of 0.73 and a beta of 1.15. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.21 and a quick ratio of 0.72. Integra LifeSciences has a 12-month low of $11.06 and a 12-month high of $32.19.

Analyst Upgrades and Downgrades

Several analysts have recently commented on IART shares. Wells Fargo & Company decreased their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. JMP Securities lowered their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. JPMorgan Chase & Co. lowered their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Finally, Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a report on Friday, April 11th. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $18.63.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds have recently made changes to their positions in IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company's stock valued at $889,000 after buying an additional 1,975 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Integra LifeSciences during the first quarter worth $277,000. Goldman Sachs Group Inc. lifted its holdings in Integra LifeSciences by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company's stock valued at $36,515,000 after purchasing an additional 35,790 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company's stock valued at $5,373,000 after purchasing an additional 45,693 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.